MétaCan
Menu
← Back to cohort

Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.

2023· article· en· W4379280728 on OpenAlexaffabout
Michael Crump, Inna Y. Gong, Zharmaine Ante, Andrew Calzavara, Matthew C. Cheung, Anca Prica

Bibliographic record

VenueJournal of Clinical Oncology · 2023
Typearticle
Languageen
FieldMedicine
TopicCOVID-19 and healthcare impacts
Canadian institutionsHealth Sciences CentreSunnybrook Health Science CentreInstitute for Clinical Evaluative SciencesUniversity Health NetworkUniversity of TorontoPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicinePandemicHazard ratioRegimenRituximabConfidence intervalPopulationInternal medicineRetrospective cohort studyProportional hazards modelCohortEmergency medicinePediatricsCoronavirus disease 2019 (COVID-19)LymphomaDiseaseInfectious disease (medical specialty)Environmental health

Abstract

fetched live from OpenAlex

e18800 Background: Due to concern for infection risk, the coronavirus disease 2019 (COVID-19) pandemic presented a unique challenge for optimal management of indolent non-Hodgkin lymphoma (iNHL). We examined treatment (trt) selection, healthcare utilization, and COVID-19 outcomes of pts with iNHL receiving first-line (1L) systemic treatment during pre-pandemic vs. pandemic period. Methods: We performed a retrospective cohort study using administrative databases in Ontario, Canada, comparing outcomes in pts with iNHL who initiated trt from, with end of follow-up Mar 31 2022. The primary outcome was trt pattern (eg, 1L regimen, rituximab [R] maintenance use); secondary outcomes were death, toxicities, healthcare utilization (emergency department visit [ED], hospitalization), SARS-CoV-2 outcomes (infection, ED visit, hospitalization/death). Adjusted hazard ratios (aHR) from cause-specific proportional hazards models were used to estimate associations between factors and outcomes. Results: We identified 4,143 pts (1,079 pandemic, 3,064 pre-pandemic), median age 69 yrs, 44% female. In both pre- and pandemic periods, bendamustine (B)+R was the most frequent prescribed regimen, with no difference in number of cycles or dose delays (Table). During the pandemic, fewer pts received R maintenance and completed the full course (aHR 0.81, 95% confidence interval [CI] 0.71-0.92, p = 0.0010) (Table). Pts treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, p < 0.0001; hospitalization aHR 0.81, 95% CI 0.70-0.94, p = 0.0067) and trt-related complications (infection aHR 0.69, 95% CI 0.57-0.82, p < 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47-0.94, p = 0.020), with no difference in death (aHR 0.79, 95% CI 0.58-1.08, p = 0.14). R use (first dose to 1 yr post last dose) was associated with higher risk of SARS-CoV-2 infection (aHR 1.56, 95% CI 1.09-2.24, p = 0.015) and COVID-19 complications (ED visit aHR 4.28, 95% CI 1.79-10.26, p = 0.0011; hospitalization/death 1.81, 95% CI 1.11-2.93, p = 0.016). Conclusions: During the pandemic, BR remained the preferred regimen for iNHL trt, while R maintenance use was less. Despite the similar 1L regimen, healthcare utilization and infectious complications were less in the pandemic cohort. R use was associated with nearly 2-fold risk of COVID-19 hospitalization/death. [Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.020
Threshold uncertainty score0.129

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.004
Science and technology studies0.0020.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.150
GPT teacher head0.482
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCOVID-19 and healthcare impacts→French-language works237,207→